Trial Profile
A Single-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Biomarker; Pharmacodynamics; Proof of concept
- Sponsors MediciNova
- 20 Jul 2020 Status changed from active, no longer recruiting to completed.
- 20 Jan 2020 Planned End Date changed from 31 Jan 2020 to 30 Jun 2020.
- 22 Oct 2019 Planned End Date changed from 1 Dec 2019 to 31 Jan 2020.